Three Core Concepts: We argue that "non-local" events require further descriptors for us to understand the degree of non-locality, what the framework of the observer describing it is, and where we humans are located relative to the ostensible non-locality. This suggests three critical factors: Relative to, from the framework of, and a hierarchy of "to what degree?" "Non-locality" without the prefix "relative" compromises its description by making it an absolute: We must scientifically ensure that, qualitatively, we can describe events that correspond with each other-like with like-and differentiate these events from those that are hierarchically dissimilar. Recognition of these levels of "relative non-locality" is important: Non-locality from "the general framework of" the infinite, or mystic or near-death experient, markedly differs theoretically from "relative to our sentient reality in three dimensions of space in the present moment (3S-1t)". Specific events may be described "relative to" our living 3S-1t reality, but conceptualized differently from the framework of observers in altered states of consciousness experiencing higher dimensions.
Levels: Hierarchical questions to ask would include IMMEDIACY PRINCIPLE: We also propose that events happening immediately, not even requiring light speed, are fundamental properties of non-local time involving more dimensions than just 3S-1t.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.explore.2014.12.007 | DOI Listing |
J Endovasc Ther
January 2025
Department of Vascular Surgery, Northwest Hospital Group, Alkmaar, The Netherlands.
Objective: There is a lack of consensus regarding the optimal antithrombotic therapy (ATT) after popliteal and infrapopliteal (PIP) endovascular therapy (EVT). Currently, dual antiplatelet therapy (DAPT) for 3 months and single antiplatelet therapy (SAPT) are the most prescribed regimens in the Netherlands. Thus far, no randomized comparison has been performed on the optimal ATT approach.
View Article and Find Full Text PDFClin Pharmacol Drug Dev
January 2025
Taiho Pharmaceutical Co., Ltd., Tokyo, Japan.
Pizuglanstat is a novel hematopoietic prostaglandin D synthase inhibitor and investigational treatment for Duchenne muscular dystrophy. This Phase 1 mass balance study aimed to characterize the absorption, metabolism, and excretion of carbon-14 (C)-labeled pizuglanstat in healthy adults (ClinicalTrials.gov, NCT04825431).
View Article and Find Full Text PDFDiabetes Obes Metab
January 2025
Research Center of Clinical Pharmacology, The First Affiliated Hospital of Yunnan University of Chinese Medicine, Kunming, China.
Objective: Previous experiments have demonstrated that BGM0504, a GLP-1R/GIPR dual agonist drug by molecular dynamics-guided optimization, had enhanced agonistic activity compared to tirzepatide. This study aims to investigate its safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) in Chinese healthy volunteers.
Methods: A randomized, double-blind, placebo-controlled and dose-escalation Phase I study was conducted as follows: a single dose (2.
Sci Prog
January 2025
Department of Hepatobiliary Surgery, Liaoning Cancer Hospital & Institute, Cancer Hospital of China Medical University, Shenyang, China.
Electrolyte imbalance management is crucial in diverse clinical scenarios, with intravenous potassium repletion often required. High-concentration infusions can pose severe complications if extravasation occurs, leading to phlebitis, local tissue damage, or in severe cases, cutaneous necrosis. This risk is elevated in geriatric patients due to factors like reduced tissue elasticity and sensitivity.
View Article and Find Full Text PDFSci Prog
January 2025
School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Purpose: The aim of this study was to evaluate the efficacy and safety of the Ahmed glaucoma valve in pediatric patients with refractory glaucoma.
Methods: A comprehensive literature search was conducted across multiple major databases, including PubMed, Embase, the Cochrane Library of Systematic Reviews, Science Direct, China's National Knowledge Infrastructure, and the Wanfang database. We retrieved studies published before December 2022 that met the inclusion criteria, including clinical controlled trials (randomized controlled trials) and clinical noncontrolled trials (non-randomized controlled trials) on the use of Ahmed glaucoma valve in pediatric patients with refractory glaucoma.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!